DLBCL

Advertisement
Patrick DalyLymphoma | October 17, 2023
Robert E. Brown, MD, and collaborating researchers from the University of Texas Health Science Center at Houston McGovern ...
Read More
Patrick DalyLymphoma | October 17, 2023
A study published in the Journal of Cancer Research and Clinical Oncology discussed outcomes of anti-CD20-based combination ...
Patrick DalyLymphoma | October 17, 2023
Data on diffuse large B-cell lymphoma (DLBCL) from the OncoCollect Lymphoma group registry were recently published in ...
Patrick DalyLymphoma | October 17, 2023
A study published in European Radiology examined the prognostic efficacy of automatic segmentation of diffuse large B-cell ...
Patrick DalyLymphoma | October 17, 2023
According to a study published in the International Journal of Radiation Oncology, Biology, Physics, approximately 50% of ...
Patrick DalyLymphoma | October 17, 2023
According to an article in Translational Cancer Research, data on the clinical outcomes of patients with primary diffuse ...
Patrick DalyLymphoma | October 17, 2023
Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLCBL) have ...
Patrick DalyLymphoma | October 17, 2023
Ferroptosis is an iron-dependent programmed cell death caused by lipid peroxidation; however, according to a study published ...
Patrick DalyLymphoma | October 17, 2023
Noting that diffuse large B-cell lymphoma (DLBCL) generally occurs in elderly individuals, researchers Cancan Luo, Han Lie, ...
Patrick DalyLymphoma | October 17, 2023
Citing an unmet clinical need in the identification and understanding of prognostic biomarkers for aggressive B-cell ...
Patrick DalyLymphoma | October 17, 2023
In a study, published in Diagnostics, researchers evaluated whether fludeoxyglucose (FDG) positron emission tomography (PET) ...
Patrick DalyLymphoma | October 17, 2023
Researchers, led by Jie Wang, MD, MS, conducted a network meta-analysis of randomized controlled trials to compare targeted ...
Patrick DalyLymphoma | October 17, 2023
In a study published in the Journal of Oral Pathology & Medicine, researchers examined the prognostic value of varying ...
Patrick DalyLymphoma | October 17, 2023
Noting a lack of data on palliative care in patients with diffuse large b-cell lymphoma (DLBCL), researchers, led by Inimfon ...
Patrick DalyLymphoma | October 17, 2023
In a review of trials on the addition of molecular targeted agents (MTAs) to the rituximab, cyclophosphamide, ...
Patrick DalyLymphoma | October 17, 2023
A study published in Leukemia & Lymphoma examined the prognostic potential of regulatory t-cells (Tregs) in patients with ...
Patrick DalyLymphoma | October 17, 2023
The SADAL trial evaluated selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL), and ...
Patrick DalyLymphoma | October 17, 2023
Citing that current clinical variables used to determine prognosis in patients with diffuse large B-cell lymphoma (DLBCL) are ...
Patrick DalyLymphoma | October 17, 2023
The phase II L-MIND study showed that tafasitamab (MOR208) combined with lenalidomide was clinically active and well ...
Patrick DalyLymphoma | October 17, 2023
According to recent research, published in Frontiers in Cell and Developmental Biology, pyroptosis—an inflammatory ...
Advertisement
Advertisement
Advertisement